Reviva pharmaceuticals announces positive safety data from drug-drug interaction clinical study of brilaroxazine

- topline data for pivotal phase 3 recover trial evaluating brilaroxazine for schizophrenia expected in mid-2023
RVPH Ratings Summary
RVPH Quant Ranking